Sanofi
SNY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SNY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SNY
Sanofi (SNY) is a global biopharmaceutical company focused on R&D-driven innovation in immunology, oncology, rare diseases, neurology, and vaccines, with a pipeline bolstered by recent acquisitions and licensing deals.
Key risk: Patent expirations and biosimilar competition
BioSniper Score
Based on 5 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 15 pipeline candidates · 591 clinical trials · 11 FDA decisions for Sanofi.
Sanofi (SNY) is a global biopharmaceutical company focused on R&D-driven innovation in immunology, oncology, rare diseases, neurology, and vaccines, with a pipeline bolstered by recent acquisitions and licensing deals.
- Sanofi reported net income of $7,851M and shareholders' equity of $74,784M as of 2025-12-31 [sec].
- The company's pipeline includes Phase 3 readouts for amlitelimab in atopic dermatitis and additions of elenestinib and SAR449028 from Blueprint Medicines [sec · filed 2026-02-17].
- Sanofi has entered into licensing agreements for ADEL-Y01 (Alzheimer's) and Gusacitinib (cGVHD), and acquired Dynavax Technologies for HEPLISAV-B [sec · filed 2026-02-17].
- R&D spending was €7,842 million in 2025, representing 18.0% of net sales [sec · filed 2026-02-17].
- The company is integrating AI across drug discovery, clinical trials, and manufacturing to improve efficiency [sec · filed 2026-02-17].
What works
- Sanofi has a diversified pipeline across five core therapeutic areas with multiple Phase 3 assets, including amlitelimab for atopic dermatitis [sec · filed 2026-02-17].
- The company is actively pursuing bolt-on acquisitions and licensing to strengthen its portfolio, such as the Dynavax and Blueprint Medicines deals [sec · filed 2026-02-17].
- Sanofi is leveraging AI and digital tools to accelerate R&D and manufacturing, with seven novel drug targets delivered in one year [sec · filed 2026-02-17].
What to weigh
- Sanofi faces significant competition from generics, biosimilars, and new therapies, especially as patents expire [sec · filed 2026-02-17].
- The company relies on third parties for discovery, manufacturing, and distribution, which introduces operational risks [sec · filed 2026-02-17].
- Pricing pressure and payer scrutiny on reimbursement are increasing, potentially impacting revenue [sec · filed 2026-02-17].
From the filings
Quoted directly from source documents.
Sanofi's pipeline includes Phase 3 readouts for amlitelimab in atopic dermatitis and additions from Blueprint Medicines.
“amlitelimab(OX40L mAb) | atopic dermatitis | Phase 3 | Positive Phase 3 study readouts (COAST 1 in 2025, and inCOAST 2 and SHORE in January 2026)”
SEC filings · February 17, 2026
Sanofi acquired Dynavax Technologies for its adult hepatitis B vaccine.
“entered into an agreement to acquire Dynavax Technologies Corporation (Dynavax), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B)”
SEC filings · February 17, 2026
Sanofi's R&D spending was €7,842 million in 2025.
“In 2025, we spent € 7,842 million on research and development, representing 18.0% of our net sales.”
SEC filings · February 17, 2026
Sanofi is using AI to accelerate drug discovery and manufacturing.
“Our R&D teams are already accelerating their work: our Target Discovery engines have delivered seven novel drug targets in just one year.”
SEC filings · February 17, 2026
Risks & what to watch (3)›
Key risks
- Patent expirations and biosimilar competition — Loss of exclusivity for key drugs could lead to significant revenue declines [sec · filed 2026-02-17].
- Dependence on third-party partners — Reliance on external parties for manufacturing and distribution creates supply chain vulnerabilities [sec · filed 2026-02-17].
- Pricing and reimbursement pressure — Increasing payer scrutiny and cost-containment measures may limit pricing flexibility [sec · filed 2026-02-17].
What to watch
- Phase 3 data for amlitelimab in atopic dermatitis and potential regulatory submissions [sec · filed 2026-02-17].
- Integration and commercial performance of acquired assets like Dynavax and Blueprint Medicines programs [sec · filed 2026-02-17].
- Progress of AI-driven R&D initiatives and their impact on pipeline velocity [sec · filed 2026-02-17].
Sources: SEC filings · Generated August 25, 2026 · How we verify sources →
Run Sanofi through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sanofi facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.77
Lead: Approved
15 candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
737
Total value held
$8.88B
| Holder | Shares | Value |
|---|---|---|
| dodge & cox | 29,504,632 | $1.42B |
| morgan stanley | 12,511,867 | $602.8M |
| bank of america corp /de/ | 9,484,350 | $457.0M |
| franklin resources inc | 7,165,193 | $345.2M |
| barrow hanley mewhinney & strauss llc | 5,887,466 | $283.7M |
| mondrian investment partners ltd | 5,040,065 | $242.8M |
| federated hermes, inc. | 4,754,359 | $229.1M |
| fmr llc | 4,010,161 | $193.2M |
| envestnet asset management inc | 3,861,894 | $186.1M |
| raymond james financial inc | 3,812,745 | $183.7M |
Showing top 10 of 737 institutional holders of Sanofi. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 0.3%
- Days to cover
- 2.0
- Shares short
- 7,398,344
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SNY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Sanofi?
Sanofi (SNY) is a global biopharmaceutical company focused on R&D-driven innovation in immunology, oncology, rare diseases, neurology, and vaccines, with a pipeline bolstered by recent acquisitions and licensing deals.
What is Sanofi's lead drug candidate?
Sanofi's most advanced tracked candidate is aubagio (Approved).
Who is the CEO of Sanofi?
Ms. Belen Garijo Lopez M.D. is the chief executive officer of Sanofi (SNY).
Where is Sanofi headquartered?
Sanofi (SNY) is headquartered in Paris, France.
What therapeutic areas does Sanofi focus on?
Sanofi develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Endocrinology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.